Next 10 |
home / stock / cslly / cslly news
2024-05-16 15:38:13 ET Summary Project $1M is a long-term buy-and-hold portfolio that aims to turn $275K into $1M by 2025 and outperform the S&P 500. 2024 has seen a positive start to the year. What's old is new - A new addition to the portfolio is a name that has been in ...
2024-05-07 05:10:21 ET Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective base...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching studen...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated ...
2024-04-24 08:31:26 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics gains as EU backs kidney disease therapy Travere Therapeutics Q4...
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligenc...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching studen...